The OJC 43: Debunking Urban Myths

 

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 43 in our series The Oncology Journal Club.

This week we have another great episode for you in our usual format.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

---

This Week’s Papers:

1. Lacouture ME, et al. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov. 2021 Apr 28:candisc.1847.2020. doi: 10.1158/2159-8290.CD-20-1847. Epub ahead of print. PMID: 33910927. Access online here. 
2. Seiwert, T.Y., et al. Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1. DOI: 10.1200/JCO.20.02046 Journal of Clinical Oncology 39, no. 1 (January 01, 2021) 1-3. Published online September 28, 2020. Access online here.
3. Korde LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28. PMID: 33507815. Access online here.

This Week’s Quick Bites:

1. Reiss KA, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021 May 10:JCO2100003. doi: 10.1200/JCO.21.00003. Epub ahead of print. PMID: 33970687. Access online here.
2. Ma W, et al. Association of Screening Lower Endoscopy With Colorectal Cancer Incidence and Mortality in Adults Older Than 75 Years. JAMA Oncol. 2021 May 20. doi: 10.1001/jamaoncol.2021.1364. Epub ahead of print. PMID: 34014275. Access online here.
3. Wallis CJD, et al. Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2021;4(5):e2110950. doi:10.1001/jamanetworkopen.2021.10950. Access online here.
4. Javle M, et al. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021 May 1;7(5):693-699. doi: 10.1001/jamaoncol.2021.0006. PMID: 33662100; PMCID: PMC7934074. Access online here.
5. Hall A, Bryant J, Sanson-Fisher R, Grady A, Proietto A, Doran CM. Top Priorities for Health Service Improvements Among Australian Oncology Patients. Patient Relat Outcome Meas. 2021 May 7;12:83-95. doi: 10.2147/PROM.S291794. PMID: 33994819; PMCID: PMC8114575. Access online here.
6. Geiger, J.L., et al. Management of Salivary Gland Malignancy: ASCO Guideline. DOI: 10.1200/JCO.21.00449 Journal of Clinical Oncology. Published online April 26, 2021 https://ascopubs.org/doi/full/10.1200/JCO.21.00449
7. Zichi C, et al. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. Eur J Cancer. 2021 May;149:49-60. doi: 10.1016/j.ejca.2021.03.007. Epub 2021 Apr 3. PMID: 33823362. Access online here.
8. Petit, C. et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. The Lancet Oncology, Volume 22, Issue 5, 727 – 736. Access online here.

Other Episodes Mentioned:

The OJC Episode 33: Was Beethoven’s death the result of medical malpractice?

The OJC Episode 34: A Manifesto for Good Trial Design

The OJC Episode 35: Sugary Drinks, Chernobyl and Meaningful Consumer Engagement

---

This Week’s Team:

Professor Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Professor Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

 

Merve AKA Christopher Jackson

Chris Jackson is a Medical Oncologist with special interest in gastrointestinal cancers, melanoma and urological cancers. Chris holds a national role in the research and management of colorectal cancer.

Chris is currently the clinical leader for oncology research at Dunedin Hospital, and has strong links with cancer trials within New Zealand. In 2015 Chris was appointed as Medical Director of the Cancer Society of New Zealand.

Chris was born and raised in Otago and is strongly committed to the region. He is a cofounder of Mercy Cancer Care, with Mercy Hospital in 2011 ensuring that patients affected by cancer are offered a full range of systemic treatments that may not otherwise be available.

Rachael Babin

Connect with us on Twitter @OncologyNewsAus